Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Atropine
Drug ID BADD_D00189
Description An alkaloid, originally from Atropa belladonna, but found in other plants, mainly solanaceae.
Indications and Usage For the treatment of poisoning by susceptible organophosphorous nerve agents having anti-cholinesterase activity (cholinesterase inhibitors) as well as organophosphorous or carbamate insecticides.
Marketing Status approved; vet_approved
ATC Code A03BA01; S01FA01
DrugBank ID DB00572
KEGG ID D00113
MeSH ID D001285
PubChem ID 174174
TTD Drug ID D0RG3O
NDC Product Code 69205-034; 11704-101; 13371-488; 11704-104; 11704-107; 11704-105; 12714-034; 11704-106; 60592-049; 63827-1015; 64181-0048
UNII 7C0697DR9I
Synonyms Atropine | Atropinol | Atropine Sulfate | Sulfate, Atropine | Atropine Sulfate Anhydrous | Anhydrous, Atropine Sulfate | Sulfate Anhydrous, Atropine | AtroPen | Atropin Augenöl | Augenöl, Atropin
Chemical Information
Molecular Formula C17H23NO3
CAS Registry Number 51-55-8
SMILES CN1C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Electrocardiogram QT prolonged13.14.05.004--
Enuresis19.07.04.001; 20.02.02.003---
Erythema23.03.06.0010.000854%-
Extensor plantar response17.02.01.005---
Extrasystoles02.03.02.003---
Eye pain06.08.03.002--
Eyelid oedema06.04.04.004; 10.01.05.001; 23.04.01.003---
Face oedema08.01.07.003; 10.01.05.002; 23.04.01.004--
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014---
Feeling hot08.01.09.009---
Flushing08.01.03.025; 23.06.05.003; 24.03.01.0020.000441%
Gastrooesophageal reflux disease07.02.02.003--
Gastrointestinal pain07.01.05.005--
Haemoglobin decreased13.01.05.003---
Haemoglobin increased13.01.05.004--
Hallucination19.10.04.0030.000138%
Hallucination, visual19.10.04.0070.000138%-
Headache17.14.01.001--
Heterophoria06.05.02.001; 17.02.05.017---
Hyperglycaemia05.06.02.002; 14.06.02.002--
Hyperhidrosis08.01.03.028; 23.02.03.0040.000138%
Hyperkinesia17.01.02.008---
Hyperpyrexia08.05.02.002---
Hyperreflexia17.02.01.002---
Hypersensitivity10.01.03.003--
Hypertension24.08.02.0010.000138%
Hyperthermia08.05.01.001; 12.05.01.0020.000207%-
Hypertonia15.05.04.007; 17.05.02.0010.000138%-
Hypoglycaemia05.06.03.001; 14.06.03.001--
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 7 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene